🇺🇸·1d agoResearch
NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Study type: INTERVENTIONAL. Phase: PHASE2, PHASE3.
Publisher
C
ClinicalTrials.gov
USA
This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- ClinicalTrials.gov
- Region
- USA
- Scope
- Research
- Published
- September 22, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Study type: INTERVENTIONAL. Phase: PHASE2, PHASE3.
Source route
Continue on clinicaltrials.gov
Leave the platform to read the original full article on the publisher site.
Source: ClinicalTrials.gov
Scope: Research
Related coverage
More related coverage
Glasgow Royal Infirmary/4h ago
Services of remembrance and support planned across NHSGGC for Baby Loss Awareness Week
Glasgow Royal Infirmary/4h ago
Glasgow Alcohol and Drug Recovery Service recognised with UK-Wide Award
St Thomas' Hospital London/4h ago
Kidney podcast opens honest conversations about organ donation
Glasgow Royal Infirmary/5h ago